abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기사

2012년 11월 28일

저자:
Sarah Boseley, Guardian [UK]

Big Pharma ups its game in providing drugs to people in poor countries

Pharmaceutical companies are doing more to help people in developing countries obtain the drugs they need, according to the latest Access to Medicines Index... GlaxoSmithKline...continues to top the league table...Johnson & Johnson and...Sanofi are now close behind. The index...has become an authoritative guide... Drug companies are scored on a range of measures, from their willingness to discount prices in poor countries, to research on neglected diseases of poor people to lobbying, transparency and conduct in clinical trials...But there are concerns that Big Pharma is not demonstrating real influence over the private contractors...[that] carry out drug trials in the developing world. [other companies in index in order of ranking: Merck & Co., Gilead Sciences, Novo Nordisk, Novartis, Merck KGaA, Bayer, Roche, Pfizer, Bristol-Myers Squibb, Abbott Laboratories, Eli Lilly, Eisai, AstraZeneca, Boehringer-Ingelheim, Takeda Pharmaceutical, Daiichi Sanyko, Astellas Pharma]